Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Using a Difficult-to-treat Resistance Index to Gauge Imbalance between Countries’ Antibiotic Resistance Prevalence and Access to Antibiotics: A Scoping Review and Concept Proposal

Antimicrobial resistance (AMR) remains a major threat that is worsened by global disparities in access to antibiotics. At the United Nations General Assembly second high-level meeting for AMR in September 2024, member nations declared a commitment to improve equitable access to antimicrobials particularly in low- and middle-income countries (LMICs).[1] However, mechanisms to capture the impact of improved antibiotic access remain unclear as access limitations do not feature within AMR definitions or burden estimates. A recent epidemiological analysis that estimated 1.14 million AMR-attributable deaths globally in 2021[2] did not consider impacts of two key treatment challenges: antibiotic access limitations or even resistance to multiple antibiotics.

 

Authors

Morgan K. Walker, Emad A. Chishti, Christina Yek, Sadia Sarzynski, Sahil Angelo, Jennifer Cohn, Alicia A. Livinski, Sameer S. Kadri

 

Read the publication